In:
Obstetrical & Gynecological Survey, Ovid Technologies (Wolters Kluwer Health), Vol. 77, No. 5 ( 2022-5), p. 277-278
Kurzfassung:
(Abstracted from Gynecol Oncol 2022;164:245–253) Cancers with genetic homologous repair defects such as the breast cancer susceptibility genes BRCA1 and BRCA2 are particularly sensitive to poly (ADP-ribose) polymerase (PARP) inhibition. Identification of other homologous recombination deficiencies (HRD) beyond BRCA loss could expand utilization of PARP inhibitors (PARPi).
Materialart:
Online-Ressource
ISSN:
1533-9866
,
0029-7828
DOI:
10.1097/01.ogx.0000827620.82650.68
Sprache:
Englisch
Verlag:
Ovid Technologies (Wolters Kluwer Health)
Publikationsdatum:
2022
ZDB Id:
2043471-6